- WHO good manufacturing practices for biological products
Good manufacturing practices (GMP) for biological products were first published by WHO in 1992 (1) This current revision reflects subsequent developments that have taken place in science and technology, and in the application of risk-based approaches to GMP (2–14) The content of this document should be considered complementary to the general recommendations set out in the current WHO good
- Biologicals - World Health Organization (WHO)
Biologicals are a class of medicines made from living cells taken from plants, animals or bacteria These cells are use in creating many types of health care products, including vaccines This group of medicines also includes products derived from human blood and plasma for the treatment of many life-threatening diseases and for surgical procedures
- Cell substrates - World Health Organization (WHO)
Cell substrates A number of biological medicinal products are derived from cells that either: naturally produce the substance desired, are genetically modified to do so, or as is the case with viral vaccines, are inoculated with vaccine virus which then replicates to produce large quantities
- Gender - World Health Organization (WHO)
Gender interacts with but is different from sex, which refers to the different biological and physiological characteristics of females, males and intersex persons, such as chromosomes, hormones and reproductive organs
- Ionizing radiation and health effects
WHO fact sheet on ionizing radiation, health effects and protective measures: includes key facts, definition, sources, type of exposure, health effects, nuclear emergencies, WHO response
- Determinants of health
Food and water are the major sources of exposure to both chemical and biological hazards They impose a substantial health risk to consumers and economic burdens on individuals, communities and nations Microorganisms such as salmonella, campylobacter, E coli O157, listeria, cholera
- ECBS 2024 - Documents
WHO BS 2024 2471 – WHO 1st International Reference panel for Adventitious Virus Detection in Biological Products by High-throughput Sequencing (HTS) Technologies WHO BS 2024 2470 – WHO 2nd International Standard for HIV-1 p24 Antigen WHO BS 2024 2469 – WHO Reference Reagent Diphtheria Antitoxin Equine
- Laboratory biosafety manual, 4th edition - World Health Organization (WHO)
This fourth edition of the manual builds on the risk assessment framework introduced in the third edition A thorough, evidence-based and transparent assessment of the risks allows safety measures to be balanced with the actual risk of working with biological agents on a case-by-case basis
|